dc.contributor.author | Feld, JJ | en_US |
dc.contributor.author | Foster, GR | en_US |
dc.date.accessioned | 2018-05-14T08:21:06Z | |
dc.date.available | 2016-07-04 | en_US |
dc.date.issued | 2016-10 | en_US |
dc.date.submitted | 2017-01-04T08:26:08.108Z | |
dc.identifier.issn | 0168-8278 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/37863 | |
dc.format.extent | S130 - S142 | en_US |
dc.relation.ispartof | JOURNAL OF HEPATOLOGY | en_US |
dc.subject | Hepatitis C virus | en_US |
dc.subject | Direct-acting antivirals | en_US |
dc.subject | Resistance-associated variants | en_US |
dc.subject | Genotype 3 | en_US |
dc.subject | Cirrhosis | en_US |
dc.subject | Chronic kidney disease (CKD) | en_US |
dc.subject | Salvage regimens | en_US |
dc.subject | Pan-genotypic | en_US |
dc.title | Second generation direct-acting antivirals - Do we expect major improvements? | en_US |
dc.type | Article | |
dc.rights.holder | © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | |
dc.identifier.doi | 10.1016/j.jhep.2016.07.007 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383932700011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 65 | en_US |